Peter G. Scheffer

Peter G. Scheffer

Auto-generated profile, based on publicly available information

Peter G. Scheffer


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2014 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
LKLona J. Kroese
Lona J. Kroese
PSPeter G. Scheffer
Peter G. Scheffer

1 August 2008 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
PSPeter G. Scheffer
Peter G. Scheffer
TTTom Teerlink
Tom Teerlink
JDJacqueline M. Dekker
Jacqueline M. Dekker
GBGriët Bos
Griët Bos
GNGiel Nijpels
Giel Nijpels
RHRobert J. Heine
Robert J. Heine
Background: Hypertriglyceridemia is a cardiovascular risk factor. Apolipoprotein C-III (apoC-III) is an important determinant of the catabolic rate of triglyceride-rich lipoproteins. The aim of this study was to investigate the prognostic value of plasma apoC-III concentrations for cardiovascular mortality.Methods: We performed this prospective study in 2244 subjects (ages 49–77 years) who participated in the Hoorn Study. During a mean follow-up of 15 years, 504 individuals died: 231 of cardiovascular disease, 180 of cancer, and 93 of other causes. Cardiovascular disease risk factors and plasma apoC-III concentrations were measured at baseline.Results: The age- and sex-adjusted plasma apoC-III concentration was prospectively associated with cardiovascular mortality (P < 0.001). After adjustment for traditional risk factors, including fasting triglycerides, the hazard ratio (95% CI) for cardiovascular death between the highest and the lowest quartile of apoC-III was 1.85 (1.02–3.38). High concentrations of apoC-III did not appear to be associated with noncardiovascular mortality.Conclusions: In this general population cohort, a high apoC-III concentration in plasma, independently of fasting triglycerides and other traditional risk factors, predicts cardiovascular mortality.

27 June 2003 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
PSP. G. Scheffer
P. G. Scheffer
GBG. Bos
G. Bos
HVH. G. F. M. Volwater
H. G. F. M. Volwater
JDJ. M. Dekker
J. M. Dekker
RHR. J. Heine
R. J. Heine
TTT. Teerlink
T. Teerlink

14 April 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
PSP. G. Scheffer
P. G. Scheffer
TTT. Teerlink
T. Teerlink
RHR. J. Heine
R. J. Heine

30 September 2009 in Clinical Biochemistry
Verified
Journal Article
Closed access
PSPeter G. Scheffer
Peter G. Scheffer
LZLeonard P. van der Zwan
Leonard P. van der Zwan
RSRoger Schindhelm
Roger Schindhelm
HVHendrikus P.A. Vermue
Hendrikus P.A. Vermue
TTTom Teerlink
Tom Teerlink

Verified
Journal Article
Open access
PDF file
SFSigrid Fischer
Sigrid Fischer
RPRoberto S. G. M. Perez
Roberto S. G. M. Perez
JNJan Nouta
Jan Nouta
WZWouter W. A. Zuurmond
Wouter W. A. Zuurmond
PSPeter G. Scheffer
Peter G. Scheffer
Exaggerated inflammation and oxidative stress are involved in the pathogenesis of Complex Regional Pain Syndrome (CRPS). However, studies assessing markers for oxidative stress in CRPS patients are limited. In this study, markers for lipid peroxidation (malondialdehyde and F2-isoprostanes) and DNA damage (8-hydroxy-2-deoxyguanosine) were measured in nine patients (mean age 50.1 ± 17.1 years) with short term CRPS-1 (median 3 months) and nine age and sex matched healthy volunteers (mean age 49.3 ± 16.8 years) to assess and compare the level of oxidative stress. No differences were found in plasma between CRPS patients and healthy volunteers for malondialdehyde (5.2 ± 0.9 µmol/L vs. 5.4 ± 0.5 µmol/L) F2-isoprostanes (83.9 ± 18.7 pg/mL vs. 80.5 ± 12.3 pg/mL) and 8-hydroxy-2-deoxyguanosine (92.6 ± 25.5 pmol/L vs. 86.9 ± 19.0 pmol/L). Likewise, in urine, no differences were observed between CRPS patients and healthy volunteers for F2-isoprostanes (117 ng/mmol, IQR 54.5–124.3 vs. 85 ng/mmol, IQR 55.5–110) and 8-hydroxy-2-deoxyguanosine (1.4 ± 0.7 nmol/mmol vs. 1.4 ± 0.5 nmol/mmol). Our data show no elevation of systemic markers of oxidative stress in CRPS patients compared to matched healthy volunteers. Future research should focus on local sampling methods of oxidative stress with adequate patient selection based on CRPS phenotype and lifestyle.